RA Capital Management
Latest statistics and disclosures from Ra Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ASND, PCVX, JANX, LEGN, RYTM, and represent 40.86% of Ra Capital Management's stock portfolio.
- Added to shares of these 10 stocks: Bicara Therapeutics (+$177M), Artiva Biotherapeutics (+$152M), PCVX (+$56M), Bioage Labs (+$46M), IDYA (+$43M), RNA (+$41M), Mbx Biosciences (+$39M), BIIB (+$39M), ACLX (+$21M), DYN (+$12M).
- Started 9 new stock positions in Artiva Biotherapeutics, AVTX, Adagio Med Hldgs, IDYA, Bicara Therapeutics, Bioage Labs, CDTX, Mbx Biosciences, XNCR.
- Reduced shares in these 10 stocks: LBPH (-$89M), VRNA (-$76M), GERN (-$63M), ASND (-$59M), URGN (-$52M), PRAX (-$27M), ELVN (-$27M), NRIX (-$14M), CYBN (-$12M), THRD (-$10M).
- Sold out of its positions in CYBN, LBPH, MGNX, NRIX, UNCY, URGN.
- Ra Capital Management was a net buyer of stock by $213M.
- Ra Capital Management has $8.7B in assets under management (AUM), dropping by 14.72%.
- Central Index Key (CIK): 0001346824
Tip: Access up to 7 years of quarterly data
Positions held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 81 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ascendis Pharma A/s - SH (ASND) | 16.7 | $1.4B | -3% | 9.7M | 149.31 |
|
| Vaxcyte SH (PCVX) | 11.4 | $993M | +5% | 8.7M | 114.27 |
|
| Janux Therapeutics SH (JANX) | 4.8 | $416M | 9.2M | 45.43 |
|
|
| Legend Biotech Corp- SH (LEGN) | 4.2 | $366M | 7.5M | 48.73 |
|
|
| Rhythm Pharmaceuticals SH (RYTM) | 3.7 | $319M | 6.1M | 52.39 |
|
|
| Avidity Biosciences SH (RNA) | 3.3 | $289M | +16% | 6.3M | 45.93 |
|
| Tyra Biosciences SH (TYRA) | 2.8 | $245M | 10M | 23.51 |
|
|
| Evolent Health Inc - A SH (EVH) | 2.8 | $241M | 8.5M | 28.28 |
|
|
| Edgewise Therapeutics SH (EWTX) | 2.7 | $238M | 8.9M | 26.69 |
|
|
| Biogen SH (BIIB) | 2.6 | $230M | +20% | 1.2M | 193.84 |
|
| Dyne Therapeutics SH (DYN) | 2.6 | $229M | +5% | 6.4M | 35.92 |
|
| Rxsight SH (RXST) | 2.2 | $194M | +6% | 3.9M | 49.43 |
|
| Bicara Therapeutics SH | 2.0 | $177M | NEW | 7.0M | 25.47 |
|
| Climb Bio SH (ELYM) | 1.8 | $160M | 31M | 5.09 |
|
|
| Ars Pharmaceuticals SH (SPRY) | 1.8 | $158M | 11M | 14.50 |
|
|
| Arcellx SH (ACLX) | 1.8 | $155M | +15% | 1.9M | 83.51 |
|
| Artiva Biotherapeutics SH | 1.8 | $152M | NEW | 9.9M | 15.45 |
|
| Wave Life Sciences SH (WVE) | 1.7 | $149M | 18M | 8.20 |
|
|
| Geron Corp SH (GERN) | 1.7 | $147M | -30% | 32M | 4.54 |
|
| Verona Pharma Plc - SH (VRNA) | 1.7 | $144M | -34% | 5.0M | 28.77 |
|
| Newamsterdam Pharma Co Nv SH (NAMS) | 1.5 | $134M | 8.1M | 16.60 |
|
|
| Apogee Therapeutics SH (APGE) | 1.3 | $115M | 2.0M | 58.74 |
|
|
| Day One Biopharmaceuticals I SH (DAWN) | 1.3 | $110M | 7.9M | 13.93 |
|
|
| 89bio SH (ETNB) | 1.2 | $105M | 14M | 7.40 |
|
|
| Recursion Pharmaceuticals-a SH (RXRX) | 1.2 | $101M | 15M | 6.59 |
|
|
| Lenz Therapeutics SH (LENZ) | 1.1 | $99M | 4.2M | 23.74 |
|
|
| Pepgen SH (PEPG) | 1.1 | $91M | 11M | 8.55 |
|
|
| Axsome Therapeutics SH (AXSM) | 1.0 | $90M | 1.0M | 89.87 |
|
|
| Structure Therapeutics SH (GPCR) | 1.0 | $83M | 1.9M | 43.89 |
|
|
| Tourmaline Bio SH (TRML) | 0.8 | $65M | 2.5M | 25.71 |
|
|
| Dianthus Therapeutics SH (DNTH) | 0.7 | $64M | 2.3M | 27.38 |
|
|
| Mineralys Therapeutics SH (MLYS) | 0.7 | $59M | 4.9M | 12.11 |
|
|
| Acrivon Therapeutics SH (ACRV) | 0.7 | $58M | 8.3M | 7.00 |
|
|
| Astria Therapeutics SH (ATXS) | 0.6 | $56M | 5.1M | 11.01 |
|
|
| 4d Molecular Therapeutics In SH (FDMT) | 0.6 | $55M | 5.1M | 10.81 |
|
|
| Cg Oncology SH (CGON) | 0.6 | $53M | 1.4M | 37.73 |
|
|
| Bicycle Therapeutics Plc- SH (BCYC) | 0.6 | $51M | 2.3M | 22.63 |
|
|
| Nkarta SH (NKTX) | 0.6 | $49M | 11M | 4.52 |
|
|
| Bioage Labs SH | 0.5 | $46M | NEW | 2.2M | 20.80 |
|
| Gh Research SH (GHRS) | 0.5 | $45M | 6.7M | 6.69 |
|
|
| Praxis Precision Medicines I SH (PRAX) | 0.5 | $44M | -38% | 762k | 57.54 |
|
| Ideaya Biosciences SH (IDYA) | 0.5 | $43M | NEW | 1.3M | 31.68 |
|
| Larimar Therapeutics SH (LRMR) | 0.5 | $40M | 6.0M | 6.55 |
|
|
| Mbx Biosciences SH | 0.5 | $39M | NEW | 1.5M | 25.98 |
|
| Acumen Pharmaceuticals SH (ABOS) | 0.4 | $37M | 15M | 2.48 |
|
|
| Fulcrum Therapeutics SH (FULC) | 0.4 | $37M | -11% | 10M | 3.57 |
|
| Iteos Therapeutics SH (ITOS) | 0.4 | $33M | -9% | 3.2M | 10.21 |
|
| Solid Biosciences SH (SLDB) | 0.3 | $30M | 4.3M | 6.97 |
|
|
| C4 Therapeutics SH (CCCC) | 0.3 | $28M | 4.9M | 5.70 |
|
|
| Enliven Therapeutics SH (ELVN) | 0.3 | $27M | -49% | 1.1M | 25.54 |
|
| Alto Neuroscience SH (ANRO) | 0.3 | $24M | 2.1M | 11.44 |
|
|
| Sera Prognostics Inc-a SH (SERA) | 0.3 | $24M | 3.0M | 7.80 |
|
|
| Taysha Gene Therapies SH (TSHA) | 0.3 | $22M | 11M | 2.01 |
|
|
| Immatics Nv SH (IMTX) | 0.2 | $20M | 1.8M | 11.41 |
|
|
| Aerovate Therapeutics SH (AVTE) | 0.2 | $19M | 9.2M | 2.09 |
|
|
| Nuvalent Inc-a SH (NUVL) | 0.2 | $18M | +47% | 176k | 102.30 |
|
| Third Harmonic Bio SH (THRD) | 0.2 | $17M | -36% | 1.3M | 13.55 |
|
| Vor Biopharma SH (VOR) | 0.2 | $16M | 23M | 0.70 |
|
|
| Insmed SH (INSM) | 0.2 | $15M | 200k | 73.00 |
|
|
| Pliant Therapeutics SH (PLRX) | 0.2 | $14M | 1.3M | 11.21 |
|
|
| Tenaya Therapeutics SH (TNYA) | 0.2 | $14M | -8% | 7.0M | 1.93 |
|
| Zura Bio SH (ZURA) | 0.2 | $13M | 3.2M | 4.06 |
|
|
| Werewolf Therapeutics SH (HOWL) | 0.2 | $13M | 6.1M | 2.12 |
|
|
| Cervomed SH (CRVO) | 0.1 | $12M | 817k | 14.60 |
|
|
| Xencor SH (XNCR) | 0.1 | $12M | NEW | 575k | 20.11 |
|
| Adicet Bio SH (ACET) | 0.1 | $11M | 7.5M | 1.44 |
|
|
| Arvinas SH (ARVN) | 0.1 | $10M | 421k | 24.63 |
|
|
| Avalo Therapeutics SH (AVTX) | 0.1 | $9.2M | NEW | 967k | 9.50 |
|
| Chimerix SH (CMRX) | 0.1 | $8.2M | 8.8M | 0.93 |
|
|
| Boundless Bio SH (BOLD) | 0.1 | $7.6M | 2.2M | 3.47 |
|
|
| Cidara Thereapeutics SH (CDTX) | 0.1 | $7.6M | NEW | 703k | 10.75 |
|
| Perceptive Capital Solutions SH (PCSC) | 0.1 | $7.5M | 750k | 10.02 |
|
|
| Lexeo Therapeutics SH (LXEO) | 0.1 | $4.9M | -18% | 547k | 9.04 |
|
| Protara Therapeutic SH (TARA) | 0.0 | $3.5M | 1.9M | 1.83 |
|
|
| Adagio Medical Holdings SH | 0.0 | $3.4M | NEW | 1.3M | 2.58 |
|
| Surrozen SH (SRZN) | 0.0 | $3.4M | 283k | 11.98 |
|
|
| Metagenomi SH (MGX) | 0.0 | $2.8M | -11% | 1.3M | 2.17 |
|
| Newamsterdam Pharma Co Nv-27 SH (NAMSW) | 0.0 | $2.3M | 333k | 7.00 |
|
|
| An2 Therapeutics SH (ANTX) | 0.0 | $2.1M | -63% | 2.0M | 1.07 |
|
| Regulus Therapeutics SH (RGLS) | 0.0 | $1.2M | -87% | 767k | 1.57 |
|
| Scilex Holding SH (SCLX) | 0.0 | $242k | 261k | 0.92 |
|
Past Filings by Ra Capital Management
SEC 13F filings are viewable for Ra Capital Management going back to 2010
- Ra Capital Management 2024 Q3 filed Nov. 14, 2024
- Ra Capital Management 2024 Q2 filed Aug. 14, 2024
- Ra Capital Management 2024 Q1 amended filed May 17, 2024
- Ra Capital Management 2024 Q1 filed May 15, 2024
- Ra Capital Management 2023 Q4 filed Feb. 14, 2024
- Ra Capital Management 2023 Q3 amended filed Nov. 15, 2023
- Ra Capital Management 2023 Q3 filed Nov. 14, 2023
- Ra Capital Management 2023 Q2 filed Aug. 14, 2023
- Ra Capital Management 2023 Q1 filed May 15, 2023
- Ra Capital Management 2022 Q4 filed Feb. 14, 2023
- Ra Capital Management 2022 Q3 filed Nov. 14, 2022
- Ra Capital Management 2022 Q2 filed Aug. 15, 2022
- Ra Capital Management 2022 Q1 filed May 16, 2022
- Ra Capital Management 2021 Q4 filed Feb. 14, 2022
- Ra Capital Management 2021 Q3 filed Nov. 15, 2021
- Ra Capital Management 2021 Q2 filed Aug. 16, 2021